PT  - JOURNAL ARTICLE
AU  - Soucy, Jean-Paul R.
AU  - Fisman, David N.
AU  - MacFadden, Derek R.
AU  - Brown, Kevin A.
TI  - Characterizing responsiveness to the COVID-19 pandemic in the United States and Canada using mobility data
AID  - 10.1101/2022.11.08.22282050
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.11.08.22282050
4099  - http://medrxiv.org/content/early/2022/11/10/2022.11.08.22282050.short
4100  - http://medrxiv.org/content/early/2022/11/10/2022.11.08.22282050.full
AB  - Background Mobile phone-derived human mobility data are a proxy for disease transmission risk and have proven useful during the COVID-19 pandemic for forecasting cases and evaluating interventions. We propose a novel metric using mobility data to characterize responsiveness to rising case rates.Methods We examined weekly reported COVID-19 incidence and retail and recreation mobility from Google Community Mobility Reports for 50 U.S. states and nine Canadian provinces from December 2020 to November 2021. For each jurisdiction, we calculated the responsiveness of mobility to COVID-19 incidence when cases were rising. Responsiveness across countries was summarized using subgroup meta-analysis. We also calculated the correlation between the responsiveness metric and the reported COVID-19 death rate during the study period.Findings Responsiveness in Canadian provinces (β = -1·45; 95% CI: -2·45, -0·44) was approximately five times greater than in U.S. states (β = -0·30; 95% CI: -0·38, -0·21). Greater responsiveness was moderately correlated with a lower reported COVID-19 death rate during the study period (Spearman’s ρ = 0·51), whereas average mobility was only weakly correlated the COVID-19 death rate (Spearman’s ρ = 0·20).Interpretation Our study used a novel mobility-derived metric to reveal a near-universal phenomenon of reductions in mobility subsequent to rising COVID-19 incidence across 59 states and provinces of the U.S. and Canada, while also highlighting the different public health approaches taken by the two countries.Funding This study received no funding.Evidence before the study There exists a wide body of literature establishing the usefulness of mobile phone-derived human mobility data for forecasting cases and other metrics during the COVID-19 pandemic. We performed a literature search to identify studies examining the opposite relationship, attempting to quantify the responsiveness of human mobility to changes in COVID-19 incidence. We searched PubMed on October 21, 2022 using the keywords “COVID-19”, “2019-nCoV”, or “SARS-CoV-2” in combination with “responsiveness” and one or more of “mobility”, “distancing”, “lockdown”, and “non-pharmaceutical interventions”. We scanned 46 published studies and found one that used a mobile phone data-derived index to measure the intensity of social distancing in U.S. counties from January 2020 to January 2021. The authors of this study found that an increase in cases in the last 7 days was associated with an increase in the intensity of social distancing, and that this effect was larger during periods of lockdown/shop closures.Added value of the study Our study developed a metric of the responsiveness of mobility to rising case rates for COVID-19 and calculated it for 59 subnational jurisdictions in the United States and Canada. While nearly all jurisdictions displayed some degree of responsiveness, average responsiveness in Canada was nearly five times greater than in the United States. Responsiveness was moderately associated with the reported COVID-19 death rate during the study period, such that jurisdictions with greater responsiveness had lower death rates, and was more strongly associated with death rates than average mobility in a jurisdiction.Implications of all the available evidence Mobile phone-derived human mobility data has proven useful in the context of infectious disease surveillance during the COVID-19 pandemic, such as for forecasting cases and evaluating non-pharmaceutical interventions. In our study, we derived a metric of responsiveness to show that mobility data may be used to track the efficiency of public health responses as the pandemic evolves. This responsiveness metric was also correlated with reported COVID-19 death rates during the study period. Together, these results demonstrate the usefulness of mobility data for making broad characterizations of public health responses across jurisdictions during the COVID-19 pandemic and reinforce the value of mobility data as an infectious disease surveillance tool for answering present and future threats.Competing Interest StatementJ-PRS has done work for the Public Health Agency of Canada outside the submitted work. DNF has served on advisory boards related to influenza and SARS-CoV-2 vaccines for Seqirus, Pfizer, AstraZeneca, and Sanofi-Pasteur Vaccines, and has served as a legal expert on issues related to COVID-19 epidemiology for the Elementary Teachers Federation of Ontario and the Registered Nurses Association of Ontario. DNF and KAB served on the Ontario COVID-19 Science Advisory Table.Funding StatementThis study received no funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The University of Toronto Research Ethics Board gave ethical approval for this work (RIS Human Protocol Number 43389).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData and code to reproduce the analysis are available at: https://github.com/jeanpaulrsoucy/covid-19-mobility-responsiveness. https://github.com/jeanpaulrsoucy/covid-19-mobility-responsiveness